DataKnowledgeCloudtrainingcoordination

L1000 LINCS DCIC REP.B023 HA1E 24H L14 duloxetine 0.74uM.tsv.gz (File)

Taxon:

Homo sapiens

Taxon (Entity type)

Subject:

HA1E

Subject (Entity type)

Project:

LINCS-2021

Project (Entity type)

File Format:

TSV

File Format (Entity type)

Dcc Asset:

datapackage.zip

Processed File (Entity type)

Dcc:

LINCS

DCC (Entity type)

Data Type:

gene expression profile

Data Type (Entity type)

Compression Format:

GZIP format

File Format (Entity type)

Biosample:

L1000 LINCS DCIC 2021 REP.B023 HA1E 24H L14 duloxetine 0.74uM

Biosample (Entity type)

Assay Type:

landmark transcript profiling assay

Assay Type (Entity type)

Anatomy:

kidney

Anatomy (Entity type)

Uncompressed Size In Bytes:270 KB

Size In Bytes:127 KB

Sha256:550897f6b687a4eedb19953a9f295af05d860090c1b25e82bb9cccff7a187221

Persistent Id:drs://drs.lincs-dcic.org/c8da56834bad6c83d757ff07bfb8bc5c

Mime Type:application/gzip

Md5:c8da56834bad6c83d757ff07bfb8bc5c

Filename:L1000_LINCS_DCIC_REP.B023_HA1E_24H_L14_duloxetine_0.74uM.tsv.gz

Creation Time:2021-01-21T00:00:00

Access Url:

drs://drs.lincs-dcic.org/c8da56834bad6c83d757ff07bfb8bc5c

Results found

Linked to

	Label	Description
	L1000 LINCS DCIC 2021 REP.B023 HA1E 24H L14 duloxetine 0.74uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 REP.B023 HA1E 24H L14 duloxetine 0.74uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

DISPLAY PER PAGE

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.